Aniracetam
Cognitive · Racetam
Tier C+
Bottom line
Read Off Label grades Aniracetam as C+ (5.7/10) based on weak evidence, variable benefit magnitude, and a low-risk safety profile.
Short plasma half-life (~1-2.
Typical use: 750-1500 mg/day PO with fat, divided doses — Rx in some EU countries; research chem in US.
What this is
Short plasma half-life (~1-2.5 hr) but active metabolites (N-anisoyl-GABA) may persist. Anecdotal reports of reduced anxiety and improved verbal fluency. Much less studied than piracetam in rigorous modern trials.
Mechanism
Positive allosteric modulator of AMPA receptors (slows desensitization); also cholinergic and serotonergic/dopaminergic modulation; fat-soluble unlike piracetam
Dose & route
750-1500 mg/day PO with fat, divided doses
Citations
- https://pubmed.ncbi.nlm.nih.gov/11346374/
- https://pubmed.ncbi.nlm.nih.gov/11607047/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3648782/
- https://pubmed.ncbi.nlm.nih.gov/39239652/
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does Aniracetam work?
- Read Off Label rates the evidence for Aniracetam as Weak and the benefit magnitude as variable, producing an overall grade of C+ (5.7/10). Short plasma half-life (~1-2.
- Is Aniracetam safe?
- Aniracetam has a low risk profile in published human data. Legal status: Rx in some EU countries; research chem in US. This is not medical advice — see the disclaimer.
- What is the typical dose for Aniracetam?
- 750-1500 mg/day PO with fat, divided doses
- How does Aniracetam work?
- Positive allosteric modulator of AMPA receptors (slows desensitization); also cholinergic and serotonergic/dopaminergic modulation; fat-soluble unlike piracetam
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.